Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital
CAR-T cell therapy is a promising treatment for acute leukemia and lymphoma. CAR-T cell therapies take a pioneering role in autologous gene therapy with three EMA-approved products. However, the chance of clinical success remains relatively low as the applicability of CAR-T cell therapy suffers from...
Main Authors: | Simon Hort, Laura Herbst, Niklas Bäckel, Frederik Erkens, Bastian Niessing, Maik Frye, Niels König, Ioannis Papantoniou, Michael Hudecek, John J. L. Jacobs, Robert H. Schmitt |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.913287/full |
Similar Items
-
Retrospective Analysis of Autologous Chondrocyte-Based Cytotherapy Production for Clinical Use: GMP Process-Based Manufacturing Optimization in a Swiss University Hospital
by: Virginie Philippe, et al.
Published: (2022-03-01) -
CAR-T State of the Art and Future Challenges, A Regulatory Perspective
by: Lorenzo Giorgioni, et al.
Published: (2023-07-01) -
Elaborating the potential of Artificial Intelligence in automated CAR-T cell manufacturing
by: Niklas Bäckel, et al.
Published: (2023-09-01) -
Towards novel reimbursement models for expensive advanced therapy medicinal products (ATMPs)
by: Dario Picecchi, et al.
Published: (2020-12-01) -
GMP-Grade Manufacturing and Quality Control of a Non-Virally Engineered Advanced Therapy Medicinal Product for Personalized Treatment of Age-Related Macular Degeneration
by: Martina Kropp, et al.
Published: (2022-11-01)